Close menu

September 15th, 2021 | 12:17 CEST

Valneva, Cardiol Therapeutics, Sartorius: Healthy returns in every market phase

  • Biotechnology
Photo credits:

The pandemic has given the healthcare sector a boost. If people were still somewhat hesitant to talk about the digitization of the healthcare system in 2019, the epidemic has clearly revealed where the weaknesses are. New drugs and procedures could also be tested under the new framework conditions. If nothing else, the industry is getting renewed attention as a result. We outline three companies and explain whether the shares have prospects or not.

time to read: 3 minutes | Author: Nico Popp
ISIN: VALNEVA SE EO -_15 | FR0004056851 , CARDIOL THERAPEUTICS | CA14161Y2006 , SARTORIUS AG O.N. | DE0007165607

Table of contents:

    Valneva: Here is what happens after the crash

    The Valneva share has caused a stir on the trading floor in recent weeks. The French Company is working on a classic inactivated vaccine against Sars-Cov2. This new vaccine could be an opportunity, especially given the remaining 25% or so of the German population who have been unable to get the shot. The assumption is that the willingness to vaccinate could increase with Valneva's vaccine. Many people are skeptical of mRNA technology, which is the basis for vaccines from BioNTech and Moderna. But the vaccine hopes surrounding Valneva have been dampened - the UK withdrew its order.

    While the approval process is expected to continue, the hopes of many shareholders have been dashed. As recently as last Friday, the share was trading around EUR 20 - and has crashed to around EUR 12.50 at present. As the order from the UK was the only major order, the situation for Valneva is serious. With such an order behind it, it is much easier to swiftly implement all the necessary investments as part of an approval process. Since analysts have also become more skeptical after the cancellation of the large order, investors should continue to be cautious about Valneva.

    Cardiol Therapeutics: Nasdaq investors are taking notice

    One company that has benefited from the Corona pandemic is Cardiol Therapeutics. The biotech Company addresses inflammatory heart disease and is in a Phase II trial with its compound CardiolRx. The Company recently received the green light from the US Food and Drug Administration (FDA). The main focus is on the safety of the active ingredient and also the positive effects on patients with acute myocarditis, i.e. inflammation of the heart muscle.

    The latter condition can occur in connection with Covid-19 but also as an extremely rare vaccination reaction. As a rule, such inflammations heal without consequences. However, patients with pre-existing conditions, obesity or permanent stress may suffer subsequent damage, and this is where Cardiol Therapeutics comes in. Cardiovascular diseases are one of the most frequent causes of death in Western countries. Cardiol's active ingredients can be regarded as safe and effective with a high degree of probability according to the current state of scientific knowledge, making the shares of Cardiol Therapeutics appear attractive. Since the stock is now listed on the Nasdaq and can attract the attention of the most important biotech investors there, speculative investors should take a closer look at the share. Currently, the value is correcting after a spectacular rise.

    Sartorius: Hidden Champion in several areas

    The Sartorius share has also experienced a spectacular rise, with the share climbing like clockwork for years. Sartorius makes disposables for drug manufacturing, laboratory instruments and other consumables. In 2020, sales of the relatively conservative Company rose a whopping 27.8%. However, since order intake grew even more dynamically simultaneously, investors need not be alarmed at all about the 2021 figures. Sartorius is benefiting from the pandemic but also from progress in the healthcare system in general. Since Sartorius is active not only in Europe (40% share of sales) but also in the Americas (approx. 34%) and Asia-Pacific (approx. 25%), the Goettingen-based Company is a true hidden champion. On top of that, there is a slim dividend.

    Although investors are unlikely to make any more big leaps with Sartorius shares, the stock could become attractive after a correction. Despite the correction, Valneva remains rather uninteresting - the withdrawal of its only customer is unsettling. On the other hand, everything is going according to plan at Cardiol Therapeutics. Here, a promising active ingredient finally seems to be getting the attention it deserves. The share is worth a look, especially during the correction.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Nico Popp on September 27th, 2023 | 07:10 CEST

    Rich as a Sheikh? Here is what's happening: Schott Pharma, BioNTech, Cardiol Therapeutics

    • Biotechnology
    • Pharma

    High-tech or add-on? When Schott Pharma's shares go public in Frankfurt on Thursday, investors are likely to have a clear opinion. The manufacturer of pharmaceutical packaging may be attracting significant interest precisely because its business model is clearly defined. But what sets Schott apart, and which companies in the pharmaceutical and biotech industry might also become interesting? We provide insights and deliver answers!


    Commented by Juliane Zielonka on September 22nd, 2023 | 06:50 CEST

    Cardiol Therapeutics, BioNTech, BYD - At top speed to new markets

    • Biotechnology
    • Pharma
    • Electromobility

    Cardiol Therapeutics is enjoying a remarkable development. The biotech company is now rolling out its ARCHER patient recruitment trial internationally at 35 participating centers. This accelerates research in the development of their therapy to combat myocarditis, a heart inflammation which has been associated with COVID-19 vaccination. For Cardiol Therapeutics, this represents an opportunity to get its therapy approved as an orphan drug. Approval is also at stake for BioNTech. With a multimillion-dollar funding boost, the Company is working on accelerated approval for a vaccine against a virus that caused quite a stir last year. The shortened development time is likely to impress investors. While business nations agree on fighting viruses, they disagree on commodities for the road. The EU would prefer to restrict BYD's successful sales on domestic roads - by imposing tariffs. BYD, meanwhile, is tapping into a completely different market.


    Commented by André Will-Laudien on September 18th, 2023 | 06:30 CEST

    Unbelievable! Hands off AI, biotech in rebound! Bayer, Defence Therapeutics, Morphosys

    • AI
    • Biotechnology
    • Investments

    The big fall decline is now over. It is always a difficult time, but the so-called "Triple Witching" went relatively smoothly this time. The European Central Bank (ECB), in its first interest rate meeting after the summer break, decided to raise key rates by another quarter point to 4.00%, up from the previous 3.75% in July. At the same time, it lowered its inflation forecast for 2025 and the outlook for economic growth in the Eurozone for the years 2023 to 2025. Economic risks are increasing, but inflation remains the determining factor for interest rates. Expectations that the US Federal Reserve (FED) will announce an interest rate pause at its next meeting on Wednesday have boosted confidence. Last week's big losers were the recently favoured AI stocks Nvidia, Microsoft and However, the biotech sector has recently started to climb again. Where are the opportunities for investors?